SkyAI, Inc 10-Q for FY2025 Q2
SkyAI, Inc. (SKYA)
About this 10-Q
SkyAI, Inc filed this 10-Q on August 13, 2025, covering the quarter ended June 30, 2025 (FY2025 Q2).
Headline figures
Quarter ended June 30, 2025, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $222.72K
- Net income
- $3.56M
- compared with a net loss of $2.1M a year earlier
- Diluted EPS
- $3.58
- compared with -$643.64 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
| TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission
file number
|
| (Exact name of registrant as specified in its charter) |
State or other jurisdiction of incorporation or organization |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of August 13, 2025, shares of the registrant’s common stock, par value $per share, were issued and outstanding.
TABLE OF CONTENTS
| PART I FINANCIAL INFORMATION | ||
| ITEM 1. | FINANCIAL STATEMENTS (Unaudited) | |
| Condensed Consolidated Balance Sheets | F-1 | |
| Condensed Consolidated Statements of Operations | F-2 | |
| Condensed Consolidated Statement of Comprehensive Income (Loss) | F-3 | |
| Condensed Consolidated Statements of Stockholders’ Equity | F-4 | |
| Condensed Consolidated Statements of Cash Flows | F-5 | |
| Notes to the Condensed Consolidated Financial Statements | F-6 | |
| ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 3 |
| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 10 |
| ITEM 4. | CONTROLS AND PROCEDURES | 10 |
| PART II OTHER INFORMATION | ||
| ITEM 1. | LEGAL PROCEEDINGS | 11 |
| ITEM 1A. | RISK FACTORS | 11 |
| ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 11 |
| ITEM 6. | EXHIBITS | 12 |
| SIGNATURES | 13 | |
| 2 |
Item 1. Financial Statements:
SHARPS TECHNOLOGY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, 2025 | December 31, 2024 | |||||||
| (Unaudited) | (Audited) | |||||||
| Assets: | ||||||||
| Current Assets | ||||||||
| Cash | $ | $ | ||||||
| Account Receivable – trade, net | ||||||||
| Tax Receivable - VAT | ||||||||
| Escrow Deposit (Note 7) | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Inventories, net (Note 3) | ||||||||
| Current Assets | ||||||||
| Fixed Assets, net of accumulated depreciation (Notes 4 and 5) | ||||||||
| Other Assets, including deposits on fixed assets (Notes 5 and 6) | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| Liabilities: | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses and other | ||||||||
| Notes Payable, net of discount (Note 7) | ||||||||
| Warrant liability (Notes 8 and 10) | ||||||||
| Total Current Liabilities | ||||||||
| Deferred Tax Liability (Note 12) | ||||||||
| Total Liabilities | ||||||||
| Commitments and Contingencies (Note 15) | ||||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, $ par value; shares authorized; shares issued and outstanding (2024: ) | ||||||||
| Common stock, $ par value; shares authorized; , shares issued and outstanding (2024: ) | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated other comprehensive income | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Stockholders’ Equity | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | $ | ||||||
The accompanying notes are an integral part of these financial statements.
| F-1 |
SHARPS TECHNOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30
(UNAUDITED)
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
THREE MONTHS ENDED JUNE 30, | SIX MONTH ENDED JUNE 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue, net | $ | $ | $ | $ | ||||||||||||
| Cost of goods manufactured | ||||||||||||||||
| Cost of goods – inventory reserve | ||||||||||||||||
| Total cost of goods manufactured | ||||||||||||||||
| Gross Margin (Loss) | ( | ) | ( | ) | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | ||||||||||||||||
| Selling, General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from Operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income (expense) | ( | ) | ||||||||||||||
| FMV adjustment on warrants | ||||||||||||||||
| Other (expense) (see Note 15) | ( | ) | ( | ) | ||||||||||||
| Foreign currency | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total Other income (expense) | ( | ) | ||||||||||||||
| Net Income (loss) Before Provision for Taxes | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Deferred Tax Benefit | ||||||||||||||||
| Net Income (loss) | ( | ) | ( | ) | ||||||||||||
| Net income (loss) per share, basic and diluted | $ | $ | ) | $ | $ | ) | ||||||||||
| Weighted average shares used to compute net income (loss) per share, basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these financial statements.
| F-2 |
SHARPS TECHNOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30
(UNAUDITED)
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
THREE MONTHS ENDED JUNE 30, | SIX MONTH ENDED JUNE 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net Income (loss) | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Other comprehensive income: | ||||||||||||||||
| Foreign currency translation adjustments | ( | ) | ( | ) | ||||||||||||
| Comprehensive Income (loss) | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
The accompanying notes are an integral part of these financial statements.
| F-3 |
SHARPS TECHNOLOGY, INC.
CONDENSED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024
(Unaudited)
| Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||
| Preferred Stock | Common Stock | Additional Paid in | Accumulated Other Comprehensive | Accumulated | Total Stockholders | |||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||
| Balance -December 31, 2023 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2024 | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Share-based compensation charges | - | - | ||||||||||||||||||||||||||||||
| Exercise of Pre-Funded Warrants | - | |||||||||||||||||||||||||||||||
| Foreign Currency Translation | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Balance - March 31, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2024 | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Share-based compensation charges | - | |||||||||||||||||||||||||||||||
| Exercise of Pre-Funded Warrants | - | |||||||||||||||||||||||||||||||
| Registration A Offering | ||||||||||||||||||||||||||||||||
| Warrant Inducements | - | |||||||||||||||||||||||||||||||
| Foreign Currency Translation | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Balance - June 30, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
SHARPS TECHNOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025
(Unaudited)
| Preferred Stock | Common Stock | Additional Paid-in | Accumulated Other Comprehensive | Accumulated | Total Stockholders’ | |||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||
| Balance – December 31, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Net income for the three months ended March 31, 2025 | - | - | ||||||||||||||||||||||||||||||
| Share-based compensation charges | - | - | ||||||||||||||||||||||||||||||
| Equity Offering - January 2025 – see Note 8 | - | |||||||||||||||||||||||||||||||
| Warrant Exercise – Series B Cashless – see Note 8 | - | ( | ) | |||||||||||||||||||||||||||||
| Foreign currency translation | - | - | ||||||||||||||||||||||||||||||
| Balance – March 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Net income for the three months ended June 30, 2025 | - | - | ||||||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||||||||
| Share-based compensation charges | ||||||||||||||||||||||||||||||||
| Warrant Exercise – Series B Cashless – see Note 8 | - | ( | ) | |||||||||||||||||||||||||||||
| Foreign currency translation | - | - | ||||||||||||||||||||||||||||||
| Balance – June 30, 2025 | ( | ) | ||||||||||||||||||||||||||||||
| Balance | ( | ) | ||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these financial statements.
| F-4 |
SHARPS TECHNOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30
(UNAUDITED)
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income (loss) | $ | $ | ( | ) | ||||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Stock-based compensation | ||||||||
| Accretion of debt discount | ||||||||
| FMV adjustment for warrants | ( | ) | ( | ) | ||||
| Escrow forfeited | ||||||||
| Inventory reserve adjustment | ||||||||
| Foreign exchange (income) loss | ( | ) | ||||||
| Changes in operating assets: | ||||||||
| Accounts receivable - trade | ( | ) | ||||||
| VAT receivable, prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Inventory | ( | ) | ( | ) | ||||
| Accounts payable and accrued liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of and deposits paid for fixed assets | ( | ) | ( | ) | ||||
| Escrow payment under agreement | ( | ) | ||||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Net proceeds from offerings and warrant exercises | ||||||||
| Repayment of Debt | ( | ) | ||||||
| Net cash provided by financing activities | ||||||||
| Effect of exchange rate changes on cash | ( | ) | ||||||
| NET INCREASE (DECREASE) IN CASH | ( | ) | ||||||
| CASH — BEGINNING OF PERIOD | ||||||||
| CASH — END OF PERIOD | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Cash Interest (OID) paid, attributed to Note (see Note 7) | $ | |||||||
| Cash paid for taxes | ||||||||
The accompanying notes are an integral part of these financial statements.
| F-5 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 1. Description of Business
Nature of Business
Sharps Technology, Inc. (“Sharps” or the “Company”) is a medical device and pharmaceutical packaging company that has designed and patented various safety syringes and has safety syringe designs that were acquired and commenced commercialization in the second quarter of 2025 by manufacturing and distribution of its products.
The accompanying consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary, Safegard Medical (Hungary) KFT, collectively referred to as the “Company.” All intercompany transactions and balances have been eliminated.
The Company’s fiscal year ends on December 31.
On
April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company
received net proceeds of $
Note 2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The
Company has not generated any cash flow from operations since inception but commenced generating revenues in the second quarter
of 2025. As of and for the six months ended June 30, 2025, the Company used cash in operations of $
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of derivative liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As of June 30, 2025, the most significant estimates relate to inventory reserves, derivative liabilities and stock-based compensation.
Cash and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of six months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions. At June 30, 2025
and December 31, 2024, the Company had $
| F-6 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 2. Summary of Significant Accounting Policies (continued)
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, which is placed with high-credit-quality financial institutions and at times exceeds federally insured limits. To date, the Company has not experienced any losses on its deposits of cash.
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess
or obsolete inventories or they may be written off. At June 30, 2025 and December 31, 2024, inventory is comprised of raw materials,
components and finished goods. During the three months ended June 30, 2025, a reserve for the negative impacts of recent market
factors, including recent global tariff assessments, has been established in the amount of $
Fair Value Measurements
ASC 820, Fair Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value.
Certain of the Company’s outstanding warrants are fair valued on a recurring basis with the trading price or FMV using Black Sholes which could cause fluctuations in operating results at the reporting periods.
Level 1
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.
Level 2
Level 2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates, maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level 3
Level 3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
| F-7 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 2. Summary of Significant Accounting Policies (continued)
Fixed Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds, computer system and website. Depreciation is calculated using the straight-line
method commencing on the date the asset is operating in the way intended by management over the following useful lives: Building –
Impairment of Long-Lived Assets
Long-lived assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.
Purchased Identified Intangible Assets
The Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years. The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. The Company evaluates the carrying value of finite-lived intangible assets on an annual basis, and an impairment charge would be recognized to the extent that the carrying amount of such assets exceeds their estimated fair value.
Stock-based Compensation Expense
The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model. For restricted stock awards, the estimated fair value is generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
| F-8 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 2. Summary of Significant Accounting Policies (continued)
Derivative Instruments
The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
At their issuance date and as of June 30, 2025, certain warrants (see Notes 8 and 10) are accounted for as liabilities as these instruments did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value is recognized in the Company’s consolidated statements of operations.
Foreign Currency Translation/Transactions
The Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations.
Comprehensive income (loss)
Comprehensive income (loss) consists of the Company’s consolidated net income (loss) and foreign currency translation adjustments related to its subsidiary. Foreign currency translation adjustments included in comprehensive income (loss) were not tax effected as the Company has a full valuation allowance at June 30, 2025 and December 31, 2024. Accumulated other comprehensive income (loss) is a separate component of stockholders’ equity and consists of the cumulative foreign currency translation adjustments.
The Company computes net income (loss) per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the consolidated statements of operations. Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Basic EPS in March 2024 included pre-funded warrants (reverse effected) (see Note 8). Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of June 30, 2025, there were stock options and warrants that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the periods presented.
| F-9 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 2. Summary of Significant Accounting Policies (continued)
Revenue
The Company generates revenue from the sale of single use syringe products or as packaging components for a customer’s product. Revenue is recorded net of sales tax, if applicable. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations, promised products are identified, the transaction price is determinable and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. The Company’s products typically have one performance obligation being the sale of a single product. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of goods manufactured.
The Company provides product warranties that: i) the products meet the terms of the customer order, ii) the products are not defective and iii) the products will conform to the descriptions set forth in their respective labeling, provided that they are used in accordance with such labeling and the Company’s written directions for use. The Company has not incurred warranty claims.
The Company’s return policy provides that a customer may return incorrect shipments or defective products within specified days following arrival at the customers facility. In all such cases, the customer must obtain an authorization from the Company. The Company has not incurred returns.
Shipping and Handling Costs
Shipping and handling costs associated with the distribution of finished goods to customers are recorded in cost of goods manufactured.
Income Taxes
The Company must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision in a subsequent period.
The provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities. The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in the period of such change.
Research and Development Costs
Research and development costs are expensed as incurred.
Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
Segment Reporting
The
Company operates as
Contingencies
Liabilities for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.
| F-10 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 2. Summary of Significant Accounting Policies (continued)
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands disclosures about a public entity’s reportable segments and requires more enhanced information about a reportable segment’s expenses, interim segment profit or loss, and how a public entity’s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The standard is effective for annual reporting periods beginning after December 15, 2023, and interim periods within years beginning after December 15, 2024. The Company adopted the standard.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires disaggregated information about the effective tax rate reconciliation and additional information on taxes paid that meet a quantitative threshold. The new guidance is effective for public companies for annual reporting periods beginning after December 15, 2024, and for non-public companies for annual reporting periods beginning after December 15, 2025, with early adoption permitted for both. The Company will adopt the new standard in the annual reporting period beginning after December 15, 2025 and is currently evaluating the impacts of the new guidance on its disclosures within the consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). The new guidance requires disaggregated information about the entity’s type of expenses into certain categories. The Company will adopt the new standard in the annual reporting period beginning after December 15, 2026 and is evaluating the impacts of the new guidance on its disclosures within the consolidated financial statements.
The Company does not expect the adoption of any accounting pronouncements to have a material impact on the consolidated financial statements.
The Company reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.
Note 3. Inventories
Inventories, net consisted of the following at June 30, 2025 and December 31, 2024:
Schedule of Inventories
| June 30, 2025 | December 31, 2024 | |||||||
| Raw materials | $ | $ | ||||||
| Work in process | ||||||||
| Finished goods | ||||||||
| Total | $ | $ | ||||||
Note 4. Fixed Assets
Fixed asset, net, as of June 30, 2025 and December 31, 2024, are summarized as follows:
Schedule of Fixed Assets, Net
| June 30, 2025 | December 31, 2024 | |||||||
| Land | $ | $ | ||||||
| Building | ||||||||
| Machinery and Equipment | ||||||||
| Computer Systems, Website and Other | ||||||||
| Total Fixed Assets | ||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||
| Fixed asset, net | $ | $ | ||||||
| F-11 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 4. Fixed Assets (continued)
Depreciation
expense of fixed assets for the six months ended June 30, 2025 and 2024 was $
Note 5. Asset Acquisition
In June 2020, the Company entered into a Share Purchase Agreement (“Agreement”) with Safegard Medical (“Safegard”) and amendments to the Agreement, collectively, the Agreements, to purchase either the stock or certain assets of a manufacturing facility for $M in cash, plus additional consideration of common stock and options with fair market values of $ and $, respectively. Through the Closing Date, the Agreements provided the Company with the exclusive use of the facility in exchange for payment of the facility’s operating costs. The monthly fee (“Operating Costs”), which primarily covered the facility’s operating costs, was mainly comprised of the seller’s workforce costs, materials and other recurring monthly operating cost.
The
acquisition of Safegard, which closed on July 6, 2022, did not meet the definition of a business pursuant to ASC 805-10, and accordingly
was accounted for as an asset acquisition in accordance with ASC 805-50. The cost of the acquisition was $
The relative fair value of the assets acquired and related deferred tax liability is as follows:
Schedule of Fair Value of Assets Acquisition
| Land | $ | |||
| Building and affixed assets | ||||
| Machinery | ||||
| Inventory | ||||
| Intangibles | ||||
| Deferred tax liability | ( | ) | ||
| Total | $ |
The
useful lives for the acquired assets is Building -
Note 6. Other Assets
Other assets as of June 30, 2025 and December 31, 2024 are summarized as follows:
Schedule of Other Assets
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Intangibles, net | $ | $ | ||||||
| Fixed asset deposits | ||||||||
| Other | ||||||||
| Total Other assets | $ | $ | ||||||
Intangibles
are related to the Asset Acquisition (see Note 5) and consist of an acquired workforce and permits. Amortization for the six months
ended June 30, 2025 and 2024 was $
| F-12 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 7. Debt Financing
On
September 20, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) and a
Senior Secured Note (the “Note”) for an aggregate principal amount of $
Note 8. Stockholders’ Equity
Capital Structure
On December 11, 2017, the Company was incorporated in Wyoming with shares of common stock authorized with a $ par value. Effective, April 18, 2019, the Company’s authorized common stock was increased to shares of common stock. The articles of incorporation also authorized preferred shares with a $ par value.
Effective
March 22, 2022, the Company completed a plan and agreement of merger with Sharps Technology, Inc., a Nevada corporation (“Sharps
Nevada”).
In July 2024, the shareholders approved the increase of the authorized common stock from to which was subsequently filed as an amendment to the articles of incorporation with the state of Nevada.
On
October 7, 2024, at a special meeting of shareholders, the shareholders approved a proposal to authorize Sharps’ Board of Directors
in its sole and absolute discretion, to file a certificate of amendment (the “Amendment”) to Sharps’ amended and restated
certificate of incorporation to effect the reverse split at a ratio to be determined by the Board, not to exceed a 1-for-22 reverse split.
A
On
April 23, 2025, under the Nevada Revised Statutes, the Board approved an Amendment to the Company’s Certificate of Incorporation
with the State of Nevada to reduce the authorized shares from to . The reduction in authorized shares, which was
effective April 27, 2025, also effectuated a reverse stock split of the outstanding common shares at a ratio of
| F-13 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 8. Stockholders’ Equity (continued)
Common Stock
On
January 29, 2025, the Company closed on an offering (the “2025 Offering”) and received gross proceeds of approximately $
The
2025 Offering consisted of (pre reverse – ) units consisting of (pre reverse – ) Common
Units with gross proceeds of $
The
Pre-Funded Warrants were immediately exercisable and could be exercised at any time until exercised in full. Immediately after closing
The 2025 Offering was made pursuant to an effective registration statement on Form S-1 (No. 333-284237) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on January 27, 2025.
The
2025 Series A Warrants are exercisable immediately and expire 60 months after stockholder approval. The 2025 Series B Warrants are
exercisable immediately and expire 30 months after stockholder approval. The exercise price of the 2025 Series A and B Warrants,
were adjusted down to $
On
December 5, 2024, the Company, entered into subscription agreements with certain institutional investors, pursuant to which the Company
agreed to issue and sell to the investors (pre reverse – ) shares (the “Shares”) of Common Stock, par value
$ per share of the Company at a price of $ per share (pre reverse -$) for gross proceeds to the Company of $
| F-14 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 8. Stockholders’ Equity (continued)
On September 23, 2024, as noted in Note 7, in connection with the Securities Purchase Agreement and Note, the Company issued 864 (pre-reverses – 259,091) shares of unregistered common stock. The shares were subsequently registered by the Company with the Security and Exchange Commission.
On
May 31 and June 13, 2024, the Company entered into subscription agreements with certain institutional investors, pursuant to which the
Company agreed to issue and sell to the investors (pre reverse - ) shares (the “Shares”) of Common Stock, par
value $ per share of the Company at a price of $ (pre reverse -$) and received gross proceeds to the Company of $
On
May 30, 2024, the Company offered warrant inducements (the “Inducement Agreement”) to certain warrant holders (the “Warrant
Holders”) which references the warrants registered for sale under both the registration statements on Form S-1 (file No. 333-263715)
and/or the registration statement on Form S-1 (File No. 333-275011) (collectively, the “Registration Statements”) for up
to a total of
On
September 29, 2023, the Company completed two simultaneous offerings and received aggregate gross proceeds of approximately $
| a. | The
first offering, the securities purchase agreement offering (the “Shelf Offering”) with institutional investors and the
Company resulted in the Company receiving net proceeds from the Shelf Offering and the sale of pre-funded warrants of approximately
$ | |
| b. | The
second offering, the securities purchase agreement offering (“Private Placement”) with institutional investors and the Company
received net proceeds from the Private Placement of approximately $ |
| F-15 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 8. Stockholders’ Equity (continued)
On
February 3, 2023, the Company completed a securities purchase agreement (“Offering”) with institutional investors and received
net proceeds from the Offering of approximately $
On
April 13, 2022, the Company’s initial public offering (“IPO”) was declared effective by the SEC pursuant to which the
Company issued and sold an aggregate of ( pre reverses -) units (“Units”),
The
Company’s common stock and warrants began trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022. The net proceeds from
the IPO, prior to payments of certain listing and professional fees were approximately $
Warrants
| a) |
a) The Company allocated the proceeds of the January 2025 Offering based on the fair values for the Series A, Series B warrants and
Prefunded Warrants. The Company determined the fair value of the Series A and Series B warrants at the Offering date using the Monte
Carlo pricing model and treated the valuation as a liability in consideration of the variable number of the issuer’s equity
shares in the warrant agreements. The fair value of the Prefunded warrants, also recorded as liability, was based on market price of
the common shares. The aggregate fair value at the Offering date was $ | |
| The remaining | ||
| Since the initial issuance of |
| F-16 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 8. Stockholders’ Equity (continued)
| b) | In
September 2024, the Company reduced the exercise price of the | |
| c) | In
connection with the Inducement Warrants in the second quarter of 2024, the Company issued (pre reverse - ) non-trading
Inducement Warrants as noted in Common Stock above. The Inducement Warrants are classified as a liability based on ASC 815 and require
remeasurement at each reporting period. The Inducement Warrants are recorded at the FMV, computed using the Black Scholes valuation
method and, recorded a FMV gain adjustment of $ | |
| d) | In
connection with an advisory agreement dated February 27, 2025, whereby the advisor and the Company agreed
In
connection with an one-year advisory services arrangement with the above third-party entered into in April 2023, the Company issued
an aggregate of | |
| e) | In
connection with the Private Placement in September 2023, the Company issued (pre-reverse -) non-trading PIPE Warrants
as a component of the Unit as noted in Common Stock above. The PIPE Warrants were recorded at the FMV, computed using the Black Sholes
valuation method. The PIPE Warrant’s liability required remeasurement at each reporting period. The PIPE Warrants were classified
as a liability based on ASC 815. For the three and six months ended June 30, 2024, the Company recorded a FMV gain adjustment of
$ | |
| f) | In
connection with the Offering in February 2023, the Company issued (pre-reverse -) non-trading warrants Offering Warrants
as a component of the Unit as noted in Common Stock above. The Offering Warrant’s liability required remeasurement at each
reporting period. The Offering Warrants were recorded at the FMV, computed using the Black Sholes valuation method. The Offering
Warrants are classified as a liability based on ASC 815. For the three and six months ended June 30, 2024 the Company recorded FMV
gain adjustments of $ | |
| g) | In
connection with the IPO in April 2022, the Company issued (pre-reverse - ) warrants (Trading Warrants) as a component
of the Units and (pre-reverse- ) warrants to the underwriter (Overallotment Warrants), as noted in Common Stock above.
The Trading and Overallotment Warrants were recorded at the FMV, being the trading price of the warrants, on the IPO effective date
and the Warrants are classified as a Liability based on ASC 815. The Warrant liability requires remeasurement at each reporting period.
During the three and six months ended June 30, 2025, the Company recorded a FMV gain adjustment of $ |
| F-17 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 8. Stockholders’ Equity (continued)
| h) | The
Company has issued (pre-reverse –) Warrants (“Note Warrants”) to the Purchasers of the Notes on April
19, 2022. The Note Warrants have an exercise price of $ | |
i) |
i)
The underwriter received (pre reverse -) warrants in connection with the IPO for a nominal cost of $ | |
Note 9. Preferred Stock
In
February 2018, the Company Board of Directors issued one share of Series A Preferred Stock to Alan Blackman, the Company’s co-founder
and Director.
In connection with final settlement with Mr. Blackman on August 2024, the Series A Preferred Stock were cancelled and forfeited without any further consideration. The Series A Preferred was returned to the status of an authorized but unissued share of preferred stock of the Company (See Note 15).
Note 10. Warrant Liability
As noted above, the 2025 Series A and 2025 Series B Warrants issued in connection with the 2025 Offering were accounted for as liabilities in accordance with ASC 815-40 and are presented as a Warrant liability in the accompanying consolidated balance sheet. The 2025 Series A and B warrants, were measured at fair value at inception. As of March 31, 2025, and thereafter, the Series A will be remeasured based on the Black Scholes method, with changes in fair value presented within the consolidated statement of operations. The Black Scholes Option-Pricing model used the following assumptions for the six months ended June 30, 2025 (See Note 8).
Schedule of Fair Value of Warrant
June 30, 2025 | ||||
| Expected term (years) | ||||
| Expected volatility | % | |||
| Risk-free interest rate | % | |||
| Dividend rate | ||||
The Warrants, arising prior to 2025, accounted for as liabilities in accordance with ASC 815-40 are presented as a Warrant liability in the accompanying June 30, 2025 condensed consolidated balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the consolidated statement of operations, The non-trading warrants, related to the February 2023, September 2023 and May 2024 offerings, were valued using the Black-Scholes pricing model. The assumptions as of the six months ended June 30, 2025, related to the May 2024 warrants only since the February and September 2023 warrants were fully exercised by December 31, 2024, and 2024 were as follows: (See Note 8)
| F-18 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 10. Warrant Liability (continued)
June 30, 2025 | June 30, 2024 | |||||||
| Expected term (years) | ||||||||
| Expected volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Dividend rate | ||||||||
The Warrant liability at June 30, 2025 and December 31, 2024 consists of the following:
Schedule of Warrant Liability
| 2025 | 2024 | |||||||
| Trading and Overallotment Warrants | $ | $ | ||||||
| Note Warrants | ||||||||
| Offering Warrants – May 2024 | ||||||||
| Offering Warrants– January 2025 – Series A | ||||||||
| Offering Warrants – January 2025 – Series B | ||||||||
| Total Warrant Liability | $ | $ | ||||||
The Warrants outstanding at June 30, 2025 and December 31, 2024, reflective of the reverse split that occurred on April 28, 2025, were as follows:
Schedule of Warrant Outstanding
June 30, 2025 | December 31, 2024 | |||||||
| Trading and Overallotment Warrants | ||||||||
| Note Warrants | ||||||||
| Offering Warrants – May 2024 | ||||||||
| Offering Warrants – January 2025 – Series A | ||||||||
| Offering Warrants – January 2025 – Series B | ||||||||
| Warrants issued for services arrangement | ||||||||
| Total Warrants Outstanding | ||||||||
For
the three and six months ended June 30, 2025 the FMV gain adjustment, which is reflected in the FMV adjustment on Warrants in the
Condensed Consolidated Statements of Operations was $
For the three and six ended June 30, 2024, the FMV
gain adjustment, which is reflected in the FMV adjustment on Warrants in the Condensed Consolidated Statements of Operations was $
On December 19, 2024, the Company’s Shareholders approved and the Board of Directors adopted the 2024 Equity Incentive Plan (the “2024 Plan”), to provide for the issuance of up to (pre reverse – ) options and/or shares of restricted stock be available for issuance to officers, directors, employees and consultants.
On January 24, 2023, the Company’s Board of Directors initially adopted the 2023 Equity Incentive Plan (the “2023 Plan”), to provide for the issuance of up to (pre -reverse - ) options and/or shares of restricted stock be available for issuance to officers, directors, employees and consultants. The 2023 Plan was subsequently updated to provide for the issuance of up to (pre-reverse – ) options and/or shares of restricted stock. The 2023 Plan was approved by shareholders at the annual meeting
| F-19 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 11. Stock Options (continued)
Schedule of Stock Options Granted and Outstanding
June 30, 2025 | ||||||||
| Options | Weighted Average Exercise Price | |||||||
| Outstanding at Beginning of year | $ | |||||||
| Granted | ||||||||
| Forfeited/cancelled | ( | ) | ||||||
| Outstanding at end of period | $ | |||||||
| Exercisable at end of period | $ | |||||||
As of June 30, 2025 and December 31, 2024, there was $ and $, respectively, of unrecognized stock-based compensation related to unvested stock options with a weighted average fair value of $ (pre reverse - $ and $ (pre reverse - $) per share, respectively, which is expected to be recognized over a weighted-average period of ten months as of June 30, 2025.
Schedule of Information About Options Outstanding
| Exercise Prices | Options Outstanding | Aggregate Intrinsic Value | Weighted Average Remaining Contractual Life | Options Exercisable | Aggregate Intrinsic Value on Exercisable Shares | |||||||||||||||||
| $ | to | |||||||||||||||||||||
| $ | to | |||||||||||||||||||||
| $ | to | |||||||||||||||||||||
| $ | ||||||||||||||||||||||
| $ | ||||||||||||||||||||||
| $ | - | |||||||||||||||||||||
| $ | ||||||||||||||||||||||
At June 30, 2025, the stock options outstanding and the options exercisable have exercise prices that exceed the stock market price at June 30, 2025 and as such, no intrinsic value exists. Intrinsic value is defined as the difference between the exercise price of the options and the market price of the Company’s common stock.
For the three and six months ended June 30, 2025, the Company recognized stock-based compensation expense of $ and $, which was recorded in selling, general and administrative expense.
For the three and six months ended June 30, 2024, the Company recognized stock-based compensation expense of $ and $ respectively, of which $ and $ was recorded in selling, general and administrative and research and development expenses, respectively.
| F-20 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 12. Income Taxes
At
the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year.
This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim
periods. Accordingly, the Company’s effective tax rate for the three and six months ended June 30, 2025 and 2024 was
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We are currently assessing its impact on our consolidated financial statements.
Note 13. Related Party Transactions and Balances
As
of June 30, 2025 and December 31, 2024, accounts payable and accrued liabilities include $
Note 14. Fair Value Measurements
The Company’s financial instruments include cash, accounts payable, notes payable and warrant liability. Cash and warrant liability are measured at fair value. Accounts payable and notes payable are measured at amortized cost and approximates fair value due to their short duration and market rate for similar instruments, respectively.
As of June 30, 2025, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Fair Value Measurements Using | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Assets | ||||||||||||||||
| Cash | $ | $ | ||||||||||||||
| Total assets measured at fair value | $ | $ | ||||||||||||||
| Liabilities | ||||||||||||||||
| Warrant liability | $ | $ | $ | |||||||||||||
| Total liabilities measured at fair value | $ | $ | $ | |||||||||||||
| F-21 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 14. Fair Value Measurements (continued)
As of December 31, 2024, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s condensed consolidated balance sheet:
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Fair Value Measurements Using | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Assets | ||||||||||||||||
| Cash | $ | $ | ||||||||||||||
| Total assets measured at fair value | $ | $ | ||||||||||||||
| Liabilities | ||||||||||||||||
| Warrant liability | $ | $ | $ | |||||||||||||
| Total liabilities measured at fair value | $ | $ | $ | |||||||||||||
Note 15. Commitments and Contingencies
Fixed Assets and Other
At
June 30, 2025, the Company had outstanding orders to purchase equipment, molds and other assets for $
Contingencies
At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies.
On
July 10, 2024, Barry Berler (“Berler”), a co-founder and former Chief Technology Officer of the Company, commenced a lawsuit
in the United States District Court for the Eastern District of New York, Barry Berler v. Sharps Technology, Inc. and Alan Blackman,
Case No. 2:24-cv-04787. In this case, Berler asserts (i) claims for damages of an aggregate of $
| F-22 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 15. Commitments and Contingencies (continued)
On
June l7, 2024, Berler filed a demand for arbitration and statement of claim under the commercial arbitration rules of the American
Arbitration Association (“AAA”) against the Company asserting claims for payment of $
On
April 3, 2024, Plastomold commenced a lawsuit against the Company in the United States District Court for the Eastern District of New
York, Plastomold Industries Ltd v. Sharps Technology, Inc., Case No. 2:24-CV-02580, asserting claims for damages in the amount of $
Royalty Agreement
In
connection with the purchase of certain intellectual property in July 2017, Barry Berler and Alan Blackman entered into a royalty agreement
which provides that Barry Berler will be entitled to a royalty of four percent (
In
September 2018, the Royalty Agreement was amended to reduce the royalty to
Employment Agreements
On
August 1, 2022, the Company cancelled the consulting agreement with Alan Blackman, Co- Chairman and Chief Operating Officer and entered
into an Employment Agreement. The Company terminated Mr. Blackman’s Employment Agreement effective May 1, 2023. Mr. Blackman continued
to serve as the Co-Chairman and a member of the Board of Directors. Subsequent to June 30, 2023, the Company and Mr. Blackman entered
into a separation agreement whereby, Mr. Blackman would be paid severance payments of approximately $
| F-23 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 15. Commitments and Contingencies (continued)
On
September 30, 2022, the Company entered into a formal employment agreement, effective on such date and will continue until terminated
by either party, subject to the terms of the agreement, with Andrew R. Crescenzo who has been serving as the Company’s Chief Financial
Officer on a contract services basis for the last three years. The agreement provided for annual compensation of $
On
November 10, 2023, the Company executed an Employment Agreement with Robert Hayes, its Chief Executive Officer amending the employment
letter dated September 6, 2021. The agreement term automatically renews for successive one-year terms as of the commencement date unless
prior written notice by either party within ninety days prior to end of the current term. The agreement provides for termination of employment
and severance benefits under stated conditions and restrictive covenants. The agreement provided for annual compensation retroactive
to June 1, 2023 of $
On
May 20, 2024, the Company entered into an Amendment to the Asset Purchase Agreement dated September 22, 2023, with Nephron and Nephron’s
InjectEZ, LLC, (collectively, the “Seller”). The September 22, 2023 agreement superseded the manufacturing and supply agreement
entered into in connection with the NPC Agreement on September 29, 2022, and the Nephron Agreement entered into on September 29, 2022.
The Amended Asset Purchase Agreement includes the purchase of certain assets. In connection with the Asset Purchase agreement, the Company
paid a non-refundable deposit of $
The closing of the Asset Purchase Agreement is contingent on obtaining further amendments and the necessary financing. There can be no assurance that the closing of the asset sale will occur.
Note 16– Segment Reporting
The accounting policies for the segment information are the same as described in Note 2- Summary of Significant Accounting Policies.
The Company commenced product revenue during the three months ended June 30, 2025.
The CODM assesses the performance of and decides how to allocate resources for the one segment based on Consolidated Net Income (Loss) Further, EBITDA (earnings before interest, taxes, depreciation and amortization), which is not presented on the face of the Consolidated Statements of Operations, is used to assist with the measurement of segment performance and allocate resources. The CODM also uses Net Income (loss) and EBITDA, to decide the level of investment in various operating activities and other capital allocation activities.
The measure of segment assets is reported on the Consolidated Balance Sheets as Consolidated Total assets.
| F-24 |
SHARPS TECHNOLOGY, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024
Note 16– Segment Reporting (continued)
The following table presents the Company’s segment results for the six months ended:
Schedule of Company’s Segment
| June 30, 2025 | June 30, 2024 | |||||||
| Revenue, net | $ | $ | ||||||
| Cost of Manufacturing | ||||||||
| Gross Margin (loss) | ( |
) | ||||||
| Expenses | ||||||||
| Research and development – Note A | ( |
) | ( |
) | ||||
| General and administrative – Note A | ( |
) | ( |
) | ||||
| Depreciation and amortization | ( |
) | ( |
) | ||||
| Interest income (expense) | ( |
) | ||||||
| FMV gain/ (loss) adjustment on warrants | ||||||||
Other income (expense) (see note 15) |
( |
) | ||||||
| Foreign currency and other | ( |
) | ( |
) | ||||
| Segment and Consolidated Net Income (loss) | $ | $ | ( |
) | ||||
| June 30, 2025 | December 31, 2024 | |||||||
| Total Consolidated Assets | $ | $ | ||||||
| Capital Expenditures and deposits paid (2025 – Six months ended; 2024 – Year Ended) | $ | $ | ||||||
Notes: (A)-net of depreciation and amortization
The following table presents the Company’s segment results for the three months ended:
| June 30, 2025 | June 30, 2024 | |||||||
| Revenue, net | $ | $ | ||||||
| Cost of Manufacturing | ||||||||
| Gross Margin (loss) | ( | ) | ||||||
| Expenses | ||||||||
| Research and development – Note A | ( | ) | ( | ) | ||||
| General and administrative – Note A | ( | ) | ( | ) | ||||
| Depreciation and amortization | ( | ) | ( | ) | ||||
| Interest income (expense) | ||||||||
| FMV gain/(loss) adjustment on warrants | ||||||||
| Foreign currency | ( | ) | ( | ) | ||||
| Other income (expense) (see note 15) | ( | ) | ||||||
| Segment and Consolidated Net Income (loss) | $ | $ | ( | ) | ||||
Notes: (A)-net of depreciation and amortization
Note 17 -Subsequent Events
Subsequent to June 30,2025, the Company executed a Subscription and Investment Agreement (the “Subscription Agreement”) with Paul Danner (“Subscriber”), the Company’s Executive Chairperson, whereby the Subscriber purchased five () shares of the Company’s Series B Preferred Stock, par value $. per share (“Securities”), which Securities shall have the rights, preferences, privileges and restrictions set forth in the Certificate of Designation. Subscriber hereby acknowledges and agrees to the entire terms of the Certificate of Designation, including, without limitation, the voting rights, the restrictions on transfer of the Securities and the redemption of the Securities pursuant of the Certificate of Designation. The purchase price paid by the Subscriber to the Company was $ per share.
On August 11, 2025, the Company notified Mr. Hayes of Non -Renewal of his Employment Agreement, as provided for under terms of the Employment Agreement (See Note 15).
On August 13, 2025, the
Company executed an Employment Agreement with Paul Danner, in connection with his appointment as the Company’s Executive
Chairperson effective July 1, 2025. Mr. Danner previously served as a Director and Audit Committee Chairperson. The agreement term automatically renews
for successive one-year terms as of the commencement date unless prior written notice by either party within ninety days prior to
end of the current term. The agreement provided for annual compensation of $
| F-25 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity and cash flows of our Company as of and for the periods presented below. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” refer to Sharps Technology, Inc.
Forward-Looking Statements
The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.
Overview
Since our inception in 2017 and through the fourth quarter of 2022, we have devoted substantially all of our resources to the research and development of our safety syringe products Commencing in the fourth quarter of 2022 we started building inventory of syringe products. We commenced revenues in the Quarter ended June 30, 2025. We have reported net income of $5,488,141, see MD&A relating to reported FMV gain of $11,087,700 on warrants, and incurred a net loss of $3,084,713 for the period six months ended June 30, 2025 and 2024, respectively. Substantially all of our net operating losses and cash used in operations resulted from costs incurred in connection with our research and development efforts, payroll and consulting fees, stock compensation and general and administrative costs associated with our operations, including costs incurred for being a public company since April 14, 2022 and in the three months ended June 30, 2025 relating to our negative Gross Margin. See Liquidity and Capital Resources and Notes to Consolidated Financial Statements.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has not generated any cash flow from operations since inception, but commenced generating revenues in the second quarter of 2025. As of June 30, 2025, the Company had working capital of $8,081,406 which is not expected to be sufficient to fund the Company’s planned operations for the next 12 months. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to commercialize its products into a profitable business or raise sufficient financing. The Company intends to finance its commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. As of the close of the January 2025 Offering and concurrent repayment of an outstanding Note, the Company is debt free.
We classify our revenues as net revenues, cost of goods manufactured and gross margin/loss and operating expenses as research and development and selling, general and administrative expenses. We maintain a corporate office located in Melville, New York, but employees and consultants in the US work remotely and will continue to do so indefinitely.
| 3 |
To remain competitive, we have built inventory because to secure orders, we require commercial quantities of inventory in order to deliver shortly after orders are placed.
Products, Marketing and Sales
We continue to be in discussions with healthcare companies and distributors for sales of our disposable syringe and prefillable syringe products. We continue to market these products to the U.S. and foreign governments. We will also look to sell our disposable syringe products to hospitals and healthcare groups as opportunities present themselves. We have received an initial purchase order under a supply agreement (See Supply Agreement in Recent Developments).
The Sharps Securegard and Sologard product lines continues to represent our disposable syringe platform commercially available to the market. These platforms have advanced features and benefits to support the needs of the market along with a high level of readiness for manufacturing and the ability to provide large commercial quantities for customers.
As previously disclosed, there continues to be insufficient capital to fund required research & development for the Sharps Provensa product line, which will affect any future commercialization. The product’s specialized technology requires further design and assembly optimization as identified in our previous commercialization efforts. This on-going product refinement process is typical of the development of new technology for the healthcare market to ensure the products are safe and effective for use every time. At this time the Company is not able to determine a timeline for future research and development and commercialization of the Provensa product.
Research and Development
Research and development expense consists of expenses incurred while performing research and development activities for our various syringe products. We recognize research and development expenses as they are incurred Substantially all of our research and development expenses to date have been incurred in connection with our syringe products.
Recent Developments
January 2025 Offering
On January 29, 2025, the Company closed on an offering (the “2025 Offering”) and received gross proceeds of approximately $20.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The net proceeds were approximately $18.2M, of which $4.2M was used to repay the outstanding Notes (see Note 7).
The 2025 Offering consisted of 47,619 (pre reverse – 14,285,714) units consisting of 30,089 (pre reverse – 9,029,814) Common Units with gross proceeds of $12.6M and 17,520 (pre reverse – 5,255,900) Pre-Funded Units with gross proceeds of $7.4M. The public offering price per Common Unit was $420 (pre reverse $1.40) or $419.97 (pre reverse $1.3999) for each Pre-Funded Unit, which is equal to the public offering price per Common Unit sold in the offering minus an exercise price of $0.0001 per Pre-Funded Warrant. Each Common Unit consisted of one share of Common Stock and each Pre-Funded Unit consisted of one pre-funded warrant to purchase one share of Common Stock. In addition, each Common Unit and Pre-Funded Unit included: (i) one Series A Registered Common Warrant to purchase one share of Common Stock per warrant at an exercise price of $87.60 (pre reverse - $1.75 and after floor price adjustment upon stockholder approval to $0.292), (“2025 Series A Warrant”) and (ii) one Series B Registered Common Warrant to purchase one share of Common Stock per warrant at an exercise price of $87.60 (pre reverse - $1.75 and after floor price adjustment upon stockholder approval to $0.292) (“2025 Series B Warrant”), collectively, the “2025 Warrants”. The 2025 Series B Warrant provides the holders with an alternative cashless exercise option, which if elected, each holder will receive three shares of Common Stock for each 2025 Series B Warrant cashless exercised. The 2025 Warrants provided for an adjustment of the original exercise price of $525 (pre reverse - $1.75) per warrant, down to an amount no less than a floor price of $87.60 (pre reverse - $0.292) per warrant upon stockholder approval. On March 28, 2025, the stockholders approved a reset and the exercise price of the 2025 Warrants was reduced to $87.60 (pre reverse - $0.292) per warrant and the number of warrants was increased so that the aggregate exercise price payable remains the same as the Offering date (See Note 8 to the Consolidated Financial Statements).
| 4 |
The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. Immediately after closing 16,603 (pre reverse – 4,980,900) of the Pre-Funded units were exercised and the Company received $498 in proceeds The underwriter, under an over- allotment option, purchased 7,143 (pre reverse- 2,142,857) 2025 Series A Warrants and 7,143 (pre reverse- 2,142,857) 2025 Series B Warrants for $0.0001 per Warrant
The 2025 Offering was made pursuant to an effective registration statement on Form S-1 (No. 333-284237) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on January 27, 2025.
Asset Purchase Agreement
On May 20, 2024, the Company entered into an Amendment to the Asset Purchase Agreement dated September 22, 2023, with Nephron and Nephron’s InjectEZ, LLC, (collectively, the “Seller”). The September 22, 2023 agreement superseded the manufacturing and supply agreement entered into in connection with the NPC Agreement on September 29, 2022, and the Nephron Agreement entered into on September 29, 2022. The Amended Asset Purchase Agreement includes the purchase of certain assets. In connection with the Asset Purchase agreement, the Company paid a non-refundable deposit of $1M to be held in escrow as a deposit on the purchase price. The Asset Purchase agreement stipulated that the $1M deposit would be maintained until July 19, 2024, at which date, if the contemplated transaction was not consummated, through no fault of the Seller, the escrow would be released to the Seller by the escrow agent. The escrow deposit of $1M was released to the Seller and recorded in Other Expense as a forfeited agreement cost in the three months ended June 30, 2024. The Company and Seller are currently not actively working towards a further amendment of the Asset Purchase Agreement. If this changes in the future, the closing of the Asset Purchase Agreement would be contingent on obtaining further amendments and the necessary financing, of which there can be no assurance.
Supply Agreement
On July 24, 2024, the Company entered into a Supply Agreement (the “Agreement”) with Stericare Solutions, LLC, a Texas limited liability company (“Stericare”), pursuant to which Stericare agreed to purchase 520 million units of 10ml polypropylene (“PP”) Sologard syringes from the Company. The specific purchase price is confidential, but revenues are expected to exceed $50 million. Under the terms of the Agreement, Stericare has committed to purchasing 520 million units of 10ml PP Sologard syringes in the following increments: 40 million units in the first year, and 120 million units each year for the remainder of the Agreement’s term. The Agreement has an initial five (5)-year term, targeted to commence in November 2024 (the “Initial Term”). Upon expiration of the Initial Term, the Agreement will automatically renew for successive one (1)-year periods (each, a “Renewal Term”), unless either party provides written notice of termination at least ninety (90) days prior to the end of the Initial Term or any Renewal Term. To date, Sharps has used pilot tooling for initial material qualifications and concept product approvals. As part of the proceeds from the recent $20 million financing, the Company has placed orders for advanced production technology for Sologard and will soon begin installation and operational qualification for the next phase of the project with Stericare. On April 30, 2025, the Company received the initial purchase order under the Agreement for $400,000. During the quarter ended June 30, 2025, the Company commenced shipments and recorded revenues under the Agreement.
The proceeds from the 2024 fundraising efforts were utilized to further increase production capacity, build inventory, and support working capital requirements. A portion of the proceeds from the January 2025 offering will be allocated to expanding production capacity in Hungary, including the purchase of advanced machinery and other facility upgrades. This expansion will facilitate the fulfillment of Securegard and Sologard, including the continued fulfillment of shipments under the aforementioned Stericare purchase order and ongoing activities with other European companies.
The Company is committed to driving revenue growth from both the Securegard and Sologard projects in 2025, as well as securing manufacturing capacity for the Company’s next generation polymer-based prefillable syringes. With the recent financing secured, the Company believes that it is positioned to advance its growth strategy by utilizing it’s working capital to support essential operating expenses. Production is currently on track, with the Company commencing revenue in the quarter ended June 30, 2025.
| 5 |
Nasdaq Compliance
On March 12, 2025, Sharps Technology, Inc. (the “Company”), was notified by the staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market as the bid price of its securities had closed at less than $1.00 per share over the previous 30 consecutive business days. Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. Further, on April 3, 2025, the Company”), was notified by the Staff of The Nasdaq that it was not in compliance with the $2,500,000 stockholders’ equity requirement for continued listing (the “Rule’) on The Nasdaq Capital Market. As reported in our Form 10-K for the fiscal year ended December 31, 2024, we reported stockholders’ equity of $1,996,129, at such time and the Company does not meet the alternatives of market value of listed securities or net income from continuing operations.
The Company presented its plan to regain compliance with the minimum bid price requirement and the net worth requirements at the Hearing on April 29, 2025. In the interim, the Company’s common stock and warrants will remain listed on Nasdaq under its existing symbols, “STSS” and “STSSW” while it awaits the hearing and Panel decision.
On May 21, 2025, the Compaany was notified by Nasdaq that the Company met the required listing requirements.
Critical Accounting Policies and Significant Judgments and Estimates
This management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The FMV adjustments, based on either the trading price or FMV of outstanding warrants classified as liabilities, could impact the operating results in the reporting periods.
Nature of Business
Sharps Technology, Inc. (“Sharps” or the “Company”) is a medical device and pharmaceutical packaging company that has designed and patented various safety syringes and has safety syringe product designs that were acquired and commenced commercialization in the second quarter of 2025i by manufacturing and distribution of its products. See Recent Developments for initial order that transitioned the Company to revenue.
The accompanying consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary, Safegard Medical, Inc, collectively referred to as the “Company.” All intercompany transactions and balances have been eliminated.
The Company’s fiscal year ends on December 31.
On April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company received net proceeds of $14.2 million on April 19, 2022. (See Capital Structure and Note 8 to the Consolidated Financial Statements)
| 6 |
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note 2 of the accompanying condensed consolidated financial statements and further discussed in our annual financial statements included in our annual report on Form 10-K for the year ended December 31, 2024.
Results of Operations
Comparison of the Three Months Ended June 30, 2025 and 2024.
| Three Months Ended | ||||||||||||||||
| June 30, 2025 | June 30, 2024 | Change | Change % | |||||||||||||
| Net Revenue | 222,722 | - | 222,722 | 100 | % | |||||||||||
| Total cost of goods manufactured | 1,254,749 | - | 1,254,749 | 100 | % | |||||||||||
| Gross Margin (Loss) | $ | (1,032,027 | ) | - | (1,032,027 | ) | -100 | % | ||||||||
| Research and development | $ | (61,455 | ) | (180,297 | ) | $ | 118,842 | 66 | % | |||||||
| Selling, General and administrative | (1,912,900 | ) | (1,740,803 | ) | (172,097 | ) | -10 | % | ||||||||
| Net Interest income (expense) | 96,953 | 5,288 | 91,665 | 1,733 | % | |||||||||||
| Other income (expense) | - | (1,000,000 | ) | 1,000,000 | -100 | % | ||||||||||
| FMV gain / (loss) adjustment on warrants | 6,468,811 | 822,130 | 5,646,681 | 687 | % | |||||||||||
| Foreign currency gain / (loss) | (75 | ) | (8,645 | ) | -8,570 | -99 | % | |||||||||
| Net gain (loss) | $ | 3,559,307 | $ | (2,102,327 | ) | $ | 5,661,634 | 269 | % | |||||||
Net Revenue/Gross Margin
For the three months ended June 30, 2025, we recognized revenues on its first sale of Securegard and Sologard syringes for $222,722, of which the supply agreement with Stericare represented 60% of the net revenue (See Recent Developments – Supply Agreement).
Given recent market factors, including the uncertainty of the global tariffs, as of June 30, 2025 a lower of cost or market (“LCM”) reserve was established. This resulted in a cost of $730,086 for the period. The remaining negative gross margin of $301,941 is principally reflective of a) excess manufacturing costs incurred of $199, 000 for labor and overhead prior to meeting planned production capacity, expected to be achieved with the receipt of and the implementation of new equipment and related qualification and b) sales at LCM vs standard cost resulting in a margin loss of $75,000.
Research and Development
For the three months ended June 30, 2025, Research and Development (“R&D”) expenses decreased to $61,455 compared to $180,297 for the three months ended June 30, 2024. The decrease of $118,842 was due to a) lower depreciation expense of $63,099 partially attributed to the 2024 impairment of certain fixed assets used in R&D and b) lower R&D labor and consulting of $55,743 given the shift in activities from R&D to manufacturing.
Selling, General and Administrative
For the three months ended June 30, 2025, Selling, General and Administrative (“G&A”) expenses were $1,912,900 as compared to $1,740,803 for the three months ended June 30, 2024. The increase of $172,097 was primarily attributable to an increase in professional services of $210,000 from $132,000 in 2024 to $342,000 in 2025 from increased legal and accounting fees. In addition, general operating costs in the manufacturing plant increased $120,000 coupled with a $16,200 increase in public company and investor relations, $11,000 increase in depreciation expense and $9,300 in travel. These increases were partially offset by lower: payroll and stock compensation ($149,800), insurance ($17,900), marketing ($8,700), rent ($8,800), computer ($3,700) and patent fees ($5,000).
Net Interest income (expense)
Net Interest income, was $96,953 for the three months ended June 30, 2025, compared to interest income of $5,288 for the three months ended June 30, 2024. Net interest changed, by $91,665 due to higher average cash balances in the current period directly related to the net proceeds from the Janaury 2025 offering.
| 7 |
Other income (expense)
Other was an expense of $1,000,000 for the three months ended June 30, 2024. An escrow deposit of $1M, relating to the Asset Purchase Agreement with Nephron, was released to the Seller on July 19, 2024, under the terms of the agreement and recorded as forfeited agreement cost (See Note 14 to the Unaudited Condensed Consolidated Financial Statements).
FMV Adjustment for Warrants
The value of certain Warrants requires the Fair Market Value (“FMV”) to be recorded at the date warrants are issued and then be remeasured at each reporting date while outstanding, with recognition of the changes in fair value to other income or expense in the Unaudited Condensed Consolidated Statement of Operations. For the three months ended June 30, 2025, the Company recorded a FMV gain adjustment of $6,468,811 to reflect the net effect of the remeasurement adjustment based on the change in market value and the decrease in number of Warrants outstanding as of June 30, 2025. (See Notes 8 and 10 to the Unaudited Condensed Consolidated Financial Statements).
Results of Operations – Six Months Ended June 30, 2025 and 2024.
| June 30, 2025 | June 30, 2024 | Change | Change % | ||||||||||||
| Net revenue | $ | 222,722 | - | $ | 222,722 | 100 | % | ||||||||
| Total cost of goods manufactured | 1,254,749 | - | 1,254,749 | 100 | % | ||||||||||
| Gross margin (loss) | (1,032,027 | ) | - | (1,032,027 | ) | -100 | % | ||||||||
| Research and development | (143,471 | ) | (377,736 | ) | 234,265 |
62 |
% | ||||||||
| Selling, general and administrative | (3,852,653 | ) | (3,387,416 |
) | (465,237 | ) | -14 |
% | |||||||
| Net interest income (expense) | (530,038 | ) | 24,312 | (554,350 | ) | -2280 |
% | ||||||||
| Other income (expense) | - |
(1,000,000 |
) | 1,000,000 |
100 | % | |||||||||
| FMV gain / (loss) adjustment for derivatives | 11,087,700 | 1,672,187 | 9,415,513 | 563 | % | ||||||||||
| Foreign currency gain / (loss) | (41,370 | ) | (16,060 | ) | (25,310 | ) | -158 |
% | |||||||
| Net gain (loss) | $ | 5,488,141 | (3,084,713 | ) | 8,572,854 | 278 |
% | ||||||||
Net Revenue / Gross Margin
For the six months ended June 30, 2025, Sharps Technology recognized its first sale of Securegard and Sologard syringes for $222,722. of which the supply agreement with Stericare represented 60% of the net revenue (See Recent Developments – Supply Agreement).
Given recent market factors, including the uncertainty of the global tariffs, as of June 30, 2025 a lower of cost or market (“LCM”) reserve was established. This resulted in a cost of $730,086 for the period. The remaining negative gross margin of $301,278 is principally reflective of a) excess manufacturing costs incurred of $199,000 for labor and overhead prior to meeting planned production capacity, expected to be achieved with the implementation of new equipment upon receipt and qualification and b) sales at LCM vs standard cost resulting in a margin loss of $75,000.
Research and Development
For the six months ended June 30, 2025, Research and Development (“R&D”) expenses decreased to $143,471 compared to $377,736 for the six months ended June 30, 2024. The decrease of $234,265 was primarily due to a shift to increased manufacturing and reduced R&D activities in 2025 as compared to the 2024 period which amounted to lower expenses of $108,000. In addition, depreciation expense decreased $126,200 partially related to non-recurring impairment of certain fixed assets in 2024.
Selling, General and Administrative
For the six months ended June 30, 2025, Selling, General and Administrative (“SG&A”) expenses were $3,852,653 as compared to $3,387,416 for the six months ended June 30, 2024. The increase of $465,237 was primarily attributable higher professional services of $363,600 from increased legal and accounting fees. In addition, general operating costs in the manufacturing plant increased $126,000, $135,500 increase in public company and investor relations, $9,000 increase in depreciation expense, $8,000 in travel, $6,800 in rent, and $14,300 in computer costs. These increases were partially offset by lower: payroll and stock compensation ($91,000), insurance ($78,700), lower marketing ($11,700), and patent fees ($16,600).
| 8 |
Net Interest income (expense)
Net Interest expense, was $530,039 for the six months ended June 30, 2025, compared to interest income of $24,312 for the six months ended June 30, 2024. Net interest changed, by $554,350 primarily due to the interest on debt charge of $708,390 in current period partially offset by higher average cash balances that generated higher interest income of $154,040.
Other income (expense)
Other was an expense of $1,000,000 for the three months ended June 30, 2024. An escrow deposit of $1M, relating to the Asset Purchase Agreement with Nephron, was released to the Seller on July 19, 2024, under the terms of the agreement and recorded as forfeited agreement cost (See Note 15 to the Unaudited Condensed Consolidated Financial Statements).
FMV Adjustment for Warrants
Certain Warrants require the Fair Market Value (“FMV”) to be remeasured at each reporting date while outstanding with recognition of the changes in fair value to other income or expense in the unaudited condensed consolidated statement of operations. For the six months ended June 30, 2025, and 2024, the Company recorded a $11,087,700 and $1,672,187 FMV gain to reflect adjustments required for outstanding Warrants liabilities. (See Notes 8 and 10 to the Unaudited Condensed Consolidated Financial Statements)
Liquidity and Capital Resources
At June 30, 2025, and December 31, 2024, we had a cash balance of $8,322,192 and $864,041, respectively. The Company had working capital of $8,081,406 at June 30, 2025 as compared to a working capital deficiency of $2,011,679 as of December 31, 2024. The increase in our working capital of $10,093,085, after net proceeds from offering in 2025 of $18,175,042, was primarily due to the use of cash of $4,355,930 in operations, investing in fixed assets purchased or payments made under orders placed of $1,959,758 and cash used to repay the short-term Note of $4,222,012. The Company intends to finance its future development and commercialization activities and its working capital needs with the recent offering proceeds and further with the sale of equity securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations are sufficient to fund working capital requirements. The Company is debt free (See Note 7 to the Unaudited Condensed Consolidated Financial Statements).
In 2024, the Company completed various offerings and private placements. (“Financings”) The proceeds from such Financings were used to fund working capital to build inventory, fund capital expenditure and operating costs.
Cash Flows
Net Cash Used in Operating Activities
The Company used cash of $4,355,930 and $3,528,676 in operating activities for the six months ended June 30, 2025 and 2024, respectively. The change in cash used was principally due to the Company incurring higher G&A expenses, increase in inventory and manufacturing costs partially offset by lower R&D activities, excluding non-cash items, as described above during the six months ended June 30, 2025.
Net Cash Used in Investing Activities
For the six months ended June 30, 2025 and 2024, the Company used cash in investing activities of $1,959,758 and $1,019,355, respectively. In both periods cash was used to acquire or pay deposits for fixed assets. In 2025, the increase is directly attributed to the aforementioned capital requirements for fulfillment under the Stericare customer order and other future business opportunities.
Net Cash Provided by Financing Activities
For the six months ended June 30, 2025, and 2024, the Company provided cash from financing activities of $13,953,030 and $2,972,348 respectively. In the 2025 period, the cash provided was from the $18,175,043 in net proceeds from the Offerings in January 2025 offset by the debt repayment of $4,222,012. In the 2024 period, the cash provided was from exercise of warrants.
Off-Balance Sheet Arrangements
During the periods presented, we did not have any off-balance sheet arrangements as defined under Regulation S-K Item 303(a)(4).
| 9 |
Emerging Growth Company Status
We are an “emerging-growth company”, as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company, we can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to avail ourselves of these options. Once adopted, we must continue to report on that basis until we no longer qualify as an emerging growth company.
We will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of the initial public offering; (ii) the first fiscal year after our annual gross revenue are $1.07 billion or more; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If, as a result of our decision to reduce future disclosure, investors find our common shares less attractive, there may be a less active trading market for our common shares and the price of our common shares may be more volatile.
We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates plus the aggregate amount of gross proceeds to us as a result of the IPO is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not required for smaller reporting companies.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation of internal controls that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 10 |
PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On July 10, 2024, Barry Berler (“Berler”), a co-founder and former Chief Technology Officer of the Company, commenced a lawsuit in the United States District Court for the Eastern District of New York, Barry Berler v. Sharps Technology, Inc. and Alan Blackman, Case No. 2:24-cv-04787. In this case, Berler asserts (i) claims for damages of an aggregate of $456,000 for defendants’ alleged (1) breach of a consulting agreement with the Company (the “Consulting Agreement”) in the amount of $52,500, (2) failure to pay a bonus with a target of $216,000 under the Consulting Agreement, (3) $187,500, representing 50% of the severance payment paid by the Company to Mr. Blackman, the Company’s co-founder and former Chief Operating Officer and Co-Chairman (ii) a declaration that Berler is the rightful owner of 50% of the Company’s Series A Preferred Stock (which preferred stock is no longer outstanding) and (iii) an injunction barring Blackman from voting the Preferred Stock and from transferring the Preferred Stock to the Company. The Company has assumed Blackman’s defense pursuant to indemnification obligations. The Company has accrued for the claim for unpaid monthly consulting fees. No amounts have been accrued for the bonus and severance claims. The Company believes that Berler’s claims are without merit and intends to defend itself vigorously. On September 17, 2024, the Company filed an answer and counterclaims with respect thereto, including for recoupment of certain compensation the Company previously paid to Berler. On February 27, 2025 the Company filed an amended answer, counterclaims and third-party claims against Berler, Plastomold Industries Ltd. (“Plastomold”), Plasto Design Ltd and Plasto Design Solutions. This case is in the discovery stage.
On June l7, 2024, Berler filed a demand for arbitration and statement of claim under the commercial arbitration rules of the American Arbitration Association (“AAA”) against the Company asserting claims for payment of $500,000 plus interest, under the Company’s royalty agreement with Berler, as amended, rescission thereof and reversion to Berler of the intellectual property rights subject thereto. The Company believes that Berler’s claims are without merit and intends to defend itself vigorously in connection with these claims. The Company filed an answer with counterclaims. This proceeding is in the discovery stage.
On April 3, 2024, Plastomold commenced a lawsuit against the Company in the United States District Court for the Eastern District of New York, Plastomold Industries Ltd v. Sharps Technology, Inc., Case No. 2:24-CV-02580, asserting claims for damages in the amount of $1.762 million for alleged (1) failure to pay invoices, of which approximately $1 million would relate to a maintenance agreement for units allegedly manufactured and sold using machinery that was defective and has never successfully produced any saleable products, (2) breach of the implied covenant of good faith and fair dealing, (3) unjust enrichment, and (4) conversion. Plastomold asserts it provided certain products and services to the Company for which its invoices were not fully paid. The Company believes that Plastomold’s claims are without merit and intends to defend itself vigorously and no amounts have been reserved at this point. On June 3, 2024, the Company filed an answer and affirmative defenses and counterclaim, which counterclaim is for damages that the Company believes would exceed the claims asserted by Plastomold, based on the insufficiency of Plastomold’s services and the results thereof, including the failure to provide machinery capable of reliably manufacturing the designated products in compliance with design specifications and functionality requirements, and with respect to which test results failed. This proceeding is in the discovery stage.
ITEM 1A. RISK FACTORS
Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in the Form 10-K for the year ended December 31, 2024, any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in the Form 10-K for the year ended December 31, 2024 except as stated below.
The Company’s operations and financial results could be adversely affected by international trade policies, including recent tariffs regulations.
We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Recent Sale of Unregistered Equity Securities
During the quarter ended June 30, 2025 no unregistered sales of equity securities occurred.
| 11 |
OTHER ITEMS
ITEM 6. EXHIBITS
| * | Filed herewith. |
| ** | Furnished herewith. |
| + | Indicates management contract or compensatory plan. |
| 12 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on this 13th day of August 2025.
| SHARPS TECHNOLOGY, INC. | |
| August 13, 2025 | /s/ Robert M. Hayes |
| Robert M. Hayes | |
Chief Executive Officer and Director (Principal Executive Officer) | |
| August 13, 2025 | /s/ Andrew R. Crescenzo |
| Andrew R. Crescenzo | |
| Chief Financial Officer | |
| (Principal Financial Officer) |
| 13 |
Exhibit 10.1
EXECUTIVE EMPLOYMENT AGREEMENT
THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into on August 13, 2025 but shall be effective as of the 1st day of July 2025, by and between Sharps Technology, Inc., a Nevada Corporation (the “Company”) and Paul K. Danner (the “Executive”) (together the Company and the Executive are the “Parties”) and supersedes and replaces any prior employment agreement or employment letter between the Parties.
W I T N E S S E T H:
WHEREAS, the Board of Directors of the Company (the “Board”) has approved the Company entering into an employment agreement with the Executive;
WHEREAS, the Executive is now the Executive Chairman of the Company and thus the key senior executive of the Company;
WHEREAS, the Executive is currently under contractual rights pursuant to an Executive Director Agreement dated May 1, 2023 between Sharps Technology, Inc., the Company and the Executive;
WHEREAS, the Company would like to enter into a revised formal agreement with the Executive to set forth the terms of Executive’s employment as well as certain termination and post-termination rights and obligations of the Parties, as further described below;
NOW THEREFORE, in consideration of the promises and mutual covenants herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
ARTICLE 1
EMPLOYMENT, TERM AND RENEWAL
1.1 Employment. The Company hereby employs Executive and Executive accepts employment as Executive Chairman of the Company. As its Executive Chairman, Executive shall render such services to the Company as are customarily rendered by the Executive Chairman of comparable companies and as required by the articles and by-laws of Employer. Executive accepts such employment and, consistent with fiduciary standards which exist between an employer and an employee, shall perform and discharge the duties commensurate with his position that may be assigned to him from time to time by the Company.
1.2 Term and Renewal. The term of this Agreement shall commence on the date first written above (the “Commencement Date”) and shall continue until the last day of the calendar year following the Commencement Date, and shall then automatically renew for successive three-month terms, unless the Company or Executive provides the other party at least 30 days’ prior written notice before the end of the First Term or any Additional Term, in which event no automatic renewal will occur (a “Notice of Non-Renewal”). For purposes of this Agreement, the first term of this Agreement (the “First Term”), and each subsequent automatic renewal shall each be considered a separate term (an “Additional Term”).
| 1 |
1.3 Compensation and Benefits. During the Term of this Agreement, the Executive shall be entitled to the compensation (“Compensation”) and benefits (“Benefits”) described in in Exhibit A attached hereto, with the understanding that, from time to time and as the Parties deem appropriate, the Parties will negotiate in good faith any other performance thresholds or other Compensation or Benefits terms that will be incorporated into Exhibit A for any Additional Term.
ARTICLE 2
TERMINATION OF EMPLOYMENT AND SEVERANCE BENEFITS
2.1 General. Executive’s employment may be terminated by the Company or Executive at any time (subject to notice obligations set forth in Section 1.2 of this Agreement) and for any reason or no reason; and upon termination of Executive’s employment, the First Term or any Additional Term, as applicable, shall end.
2.2 Termination By The Company For Cause Or By Non-Renewal of Agreement. If the Executive’s employment is terminated by the Company for Cause or by the Company pursuant to a Notice of Non-Renewal (including for no reason), then the Executive shall only be entitled to his earned but unpaid “Base Salary”, as described in Section 1 of Exhibit A, and Benefits owing to Executive under the terms of any employee benefits under Sections 7 and 8 of Exhibit A (the “Accrued Benefits”). For purposes of this Agreement, Accrued Benefits shall include any unused vacation time which has accrued during the Term in which the Executive’s employment is terminated, but shall not include any accrued vacation from prior Terms.
2.3 Termination By The Company Without Cause. If the Executive’s employment is terminated by the Company without Cause, then the Executive shall only be entitled to the Severance Benefits as described in Section 2.9 of this Agreement as well as his Accrued Benefits.
2.4 Termination By The Executive For Good Reason. If the Executive’s employment is terminated by the Executive for Good Reason, then the Executive shall only be entitled to the Severance Benefits as described in Section 2.9 of this Agreement as well as his Accrued Benefits.
2.5 Termination By The Executive Without Good Reason. If the Executive’s employment is terminated by the Executive without Good Reason, then the Executive shall only be entitled to his earned but unpaid Base Salary as well as his Accrued Benefits.
2.6 Termination By The Executive By Non-Renewal of Agreement. If the Executive’s employment is terminated by the Executive pursuant to a Notice of Non-Renewal (including for no reason), then the Executive shall only be entitled to his earned but unpaid Base Salary (as described in Exhibit A) as well as his Accrued Benefits.
2.7 Termination By Death. If the Executive’s employment is terminated by his death, Executive’s estate, survivors or beneficiaries (as the case may be) shall only be entitled to receive Severance Benefits as described in Section 2.9 of this Agreement, Accrued Benefits, and unpaid Reverse Takeover Bonus, if eligible.
| 2 |
2.8 Termination By Disability. During any period that Executive is unable to perform Executive’s duties hereunder as a result of a disability prior to the termination of Executive’s employment for a “permanent and total disability” (within the meaning Section 22(e)(3) of Internal Revenue Code of 1986, as amended the “Code”), Executive shall continue to receive Executive’s full Base Salary and Benefits until Executive’s employment is terminated pursuant to this Section. Upon termination of Executive’s employment hereunder as a result of Executive’s permanent and total disability, Executive shall only be entitled to the Severance Benefits as described in Section 2.9 of this Agreement as well as his Accrued Benefits.
2.9 Severance Benefits. In the event that the Executive becomes entitled to receive severance benefits pursuant to Sections 2.3, 2.4, 2.7 or 2.8 of this Agreement, the Company shall pay and provide the Executive with the following “Severance Benefits”:
| a) | Within 30 days after the date of termination, which is hereby defined as the date on which the Executive’s employment with the Company terminates for any reason, and for a period of thee (3) months after the date of termination, one-third (1/3) of the Executive’s then current annual Base Salary per month, less any taxes and withholding as may be necessary pursuant to law, to be paid in accordance with the Company’s normal payroll practices, but in no event less frequently than monthly. |
As a condition to receiving payments contemplated by Section 2.9, within 30 days after the effective date of such termination, Executive shall execute and deliver, and not have revoked, a separation agreement and general release in favor of the Company and its affiliates in such form as is mutually agreeable to the Company and Executive. Notwithstanding anything herein to the contrary, in the event such 30-day period falls into two (2) calendar years, the payments contemplated in this Section 2.9 shall not commence until the second calendar year and within the above-referenced 30-day period. The Severance Benefits shall terminate immediately upon the Executive violating any of the provisions of Article III of this Agreement.
2.10 Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following, without the Executive’s prior written consent: (i) a material diminution of Executive’s title, authority, duties or responsibilities, (ii) a material reduction in Executive’s Base Salary or Benefits, (iii) any requirement that the Executive report to anyone other than the Board, or (iv) any material breach of this Agreement by the Company. However, none of the foregoing events or conditions will constitute Good Reason unless: (x) the Executive provides the Company with written objection to the event or condition within 60 days following the event or condition, (y) the Company does not “cure” the event or condition within 30 days of receiving that written objection, and (z) the Executive terminates his employment within 30 days following the expiration of that cure period.
2.11 Cause. For purposes of this Agreement, “Cause” shall be deemed to exist upon any of the following events: (i) the Executive’s commission or conviction of, or plea of guilty or nolo contendere, to a felony, a crime involving fraud or moral turpitude or any other crime relating to the Company which would reasonably be expected to be materially injurious to the Company; (ii) the Executive abuses alcohol and/or drugs in a manner that materially impacts his ability to successfully perform his duties under this Agreement; (iii) failure to substantially perform Executive’s essential job functions as directed by the Board; (iv) Executive’s material misconduct or gross negligence; (v) Executive’s material violation of any Company policy; or (vi) any material breach of this Agreement; provided that: (a) a termination of Executive’s employment for Cause that is susceptible to cure shall not be effective unless the Company first gives Executive written notice of its intention to terminate and the grounds for such termination, and Executive has not, within thirty (30) business days following receipt of such notice, cured such Cause, it being understood that subparts (ii), (iii), (iv), (v) and (vi) are curable; (b) the failure of the Company to achieve budgeted or projected financial or similar performance objectives shall not, in and of itself, be considered a breach of any obligation under this Agreement or to otherwise constitute “Cause” as defined herein.
| 3 |
ARTICLE 3
RESTRICTIVE COVENANTS
3.1 Covenant not to Compete. Executive agrees that, during Executive’s employment with the Company and until the first anniversary of Executive’s termination of employment (except in the event of Executive’s “permanent and total disability”) (“Non-Compete Period”), Executive shall not become employed by or associated with as employee, consultant, director, or in any other equivalent capacity, any company engaged in the manufacture, distribution, or sale of products or services substantially similar to those offered by the Company during the Executive’s employment.
| a) | If Executive’s employment is terminated: by the Company for Cause; or by the Company pursuant to a Notice of Non-Renewal (including for no reason); or by the Executive pursuant to a Notice of Non-Renewal (including for no reason); or by the Executive without Good Reason, the Company and Executive agree that the Company will provide no additional consideration to Executive (or his estate, survivors or beneficiaries, as the case may be), to support the enforcement of the covenant not to compete. |
| b) | If Executive’s employment is terminated: by the Company without Cause; or by the Executive for Good Reason; or because of Executive’s “permanent and total disability,” the Company and Executive agree that the Company’s provision of Severance Benefits as described in Section 2.9 of this Agreement will support the enforcement of the covenant not to compete for the shorter of the Non-Compete Period or an amount proportionate to the period of time the Company, in its sole discretion, elects to enforce the covenant not to compete. |
3.2 Covenant not to Solicit. Executive agrees that, during Executive’s employment, and until the one (1) year anniversary of Executive’s termination of employment (“Non-Solicit Period”), Executive shall not directly or indirectly solicit for employment or employ any person, who is or was employed by the Company within one (1) year prior to Executive’s termination of employment, in any business in which the Executive has a material interest (meaning where Executive does, directly or indirectly, own 5% or more of any class of securities of such interest), as an officer, manager, partner, shareholder or beneficial owner. Further, during the Non-Solicit Period, Executive will not assist or encourage any employee of the Company to cease working for the Company.
| 4 |
3.3 Confidentiality and Nondisclosure. The Executive will not use or disclose to any individual or entity any Confidential Information (as defined below) except (i) in the performance of Executive’s duties for the Company, (ii) as authorized in writing by the Company, or (iii) as required by subpoena or court order, provided that, prior written notice of such required disclosure is provided to the Company and, provided further that all reasonable efforts to preserve the confidentiality of such information shall be made. As used in this Agreement, “Confidential Information” shall mean information that (i) is used or potentially useful in the business of the Company, (ii) the Company treats as proprietary, private or confidential, and (iii) is not generally known to the public. “Confidential Information” includes, without limitation, information relating to the Company’s products or services, processing, manufacturing, marketing, selling, customer lists, call lists, customer data, memoranda, notes, records, technical data, sketches, plans, drawings, chemical formulae, trade secrets, composition of products, research and development data, sources of supply and material, operating and cost data, financial information, personal information and information contained in manuals or memoranda. “Confidential Information” also includes proprietary and/or confidential information of the Company’s customers, suppliers and trading partners who may share such information with the Company pursuant to a confidentiality agreement or otherwise. The Executive agrees to treat all such customer, supplier or trading partner information as “Confidential Information” hereunder. The foregoing restrictions on the use or disclosure of Confidential Information shall continue after Executive’s employment terminates for any reason for so long as the information is not generally known to the public.
3.4 Non-Disparagement. The Executive will not at any time during his employment with the Company, or after the termination of his employment with the Company, directly or indirectly (i) disparage, libel, defame, ridicule or make negative comments regarding, or encourage or induce others to disparage, libel, defame, ridicule or make negative comments regarding, the Company, or any of the Company’s officers, directors, employees or agents, or the Company’s products, services, business plans or methods (it being understood that comments made in Executive’s good faith performance of Executive’s duties hereunder shall not be deemed disparaging or defamatory for purposes of this Agreement); or (ii) engage in any conduct or encourage or induce any other person to engage in any conduct that is in any way injurious or potentially injurious to the reputation or interests of the Company or any of the Company’s, officers, directors, employees or agents. The Company will instruct the members of the Board of Directors as well as the Company’s officers and anyone who is authorized to make any public statement on behalf of the Company, not to make, or direct any other person, entity or interest to make, any Disparaging Statement about Executive. For purposes of this Agreement, a “Disparaging Statement” shall mean any communication that is intended to defame or disparage, or has the effect of defaming or disparaging.
3.5 Restrictions Reasonable. Executive acknowledges that the restrictions under this Article III are substantial, and may effectively prohibit him from working for a period of one year in the field of his experience and expertise. Executive further acknowledges that he has been given access and shall continue to be given access to all of the Confidential Matters and trade secrets described above during the course of his employment, and therefore, the restrictions are reasonable and necessary to protect the competitive business interests and goodwill of the Company and do not cause Executive undue hardship.
| 5 |
3.6 Survival of Restrictive Covenants. Executive’s obligations under this Article III of the Agreement shall survive Executive’s termination of employment with the Company and the termination of this Agreement.
3.7 Equitable Relief. Executive hereby acknowledges and agrees that the Company and its goodwill would be irreparably injured by, and that damages at law are an insufficient remedy for, a breach of the provisions of this Agreement, and agrees that the Company, in addition to other remedies available to it for such breach shall be entitled to seek a preliminary injunction, temporary restraining order, or other equivalent relief, restraining Executive from any actual breach of the provisions hereof, and that the Company’s rights to such equitable relief shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled.
3.8 Nothing in this Agreement generally and in Section 3.3 specifically, will (or should be construed to): (i) interfere with Executive’s right and responsibility to give truthful testimony under oath; (ii) restrict Executive’s ability to communicate information regarding wages or terms and conditions of his employment with Sharps; (iii) prohibit Executive from disclosing the information contained in this Agreement to the Equal Employment Opportunity Commission (“EEOC”) or any state agency responsible for enforcing anti-discrimination laws; or (iv) preclude Executive from participating in an investigation, filing a charge, or otherwise communicating with the EEOC or any other fair employment agency, but, in connection with any such charge or proceeding, Executive will have no personal right to any monetary recovery of any kind. Consistent with Rule 21F-17 of the Securities Exchange Act of 1934, any confidentiality and non-disclosure provisions in this Agreement or arising from this Agreement do not prohibit or restrict Executive (or his attorneys) from: initiating communications directly with, or responding to any inquiry from, or providing testimony before, the U.S. Securities and Exchange Commission, NASD/FINRA, any other self-regulatory organization, any other state or federal regulatory authority or pursuant to court or administrative proceedings. In broadest terms, nothing herein is intended to impede any governmental investigation, Executive’s ability to report potential violations of the federal and state securities laws or Executive’s participation in any whistleblower rewards program.
ARTICLE 4
MISCELLANEOUS
4.1 Entire Agreement. This Agreement contains the entire understanding of the Company and the Executive with respect to the subject matter hereof.
4.2 Prior Agreement. This Agreement supersedes and replaces any prior oral or written employment or severance agreement between the Executive and the Company.
4.3 Subsidiaries. Where appropriate in this Agreement, including all of Article 2, the term “Company” shall also include any direct or indirect subsidiaries of the Company.
4.4 D&O Insurance; Indemnification. In addition to any indemnification rights that Executive may have under the Company’s bylaws, while employed by the Company and continuing until the later of the sixth anniversary of the termination of Executive’s employment and the date on which all claims against Executive that would otherwise be covered by such policy (or policies) become fully time-barred, the Company shall purchase and maintain, at its own expense, directors’ and officers’ liability insurance providing coverage to Executive on terms that are no less favorable than the coverage provided to directors and senior executives of the Company. The Company agrees that if Executive is made a party, or is threatened to be made a party, to any action, suit or proceeding, whether civil, criminal, administrative or investigative (each, a “Proceeding”), by reason of the fact that he is or was a director, officer or employee of the Company or is or was serving at the request of the Company as a director, officer, member, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether or not the basis of such Proceeding is Executive’s alleged action in an official capacity while serving as a director, officer, member, employee or agent, in each case, whether on, prior to, or following the Effective Date, Executive shall be indemnified and held harmless by the Company to the fullest extent permitted or authorized by applicable law and the Company’s bylaws, against all cost, expense, liability and loss reasonably incurred or suffered by Executive in connection therewith, and such indemnification shall continue as to Executive even if he has ceased to be a director, member, employee or agent of the Company or other entity and shall inure to the benefit of Executive’s heirs, executors and administrators. The Company may promptly advance to Executive all reasonable costs and expenses incurred by Executive in connection with any such action, suit or proceeding provided that Executive furnishes the Company with a written undertaking, executed personally or on Executive’s behalf, to repay any advances if it is ultimately determined that Executive is not entitled to be indemnified by the Company.
| 6 |
4.5 Compliance with Code Section 409A.
| a) | General. It is the intention of both the Company and Executive that the benefits and rights to which Executive could be entitled pursuant to this Agreement comply with Section 409A of the Internal Revenue Code, and its implementing regulations and guidance (“Section 409A”), to the extent that the requirements of Section 409A are applicable thereto, and the provisions of this Agreement shall be construed in a manner consistent with that intention. |
| b) | Distributions on Account of Separation from Service. If and to the extent required to comply with any payment or benefit required to be paid under this Agreement on account of termination of Executive’s employment, service (or any other similar term) shall be made only in connection with a “separation from service” with respect to Executive within the meaning of Section 409A. |
| c) | Six Month Delay for Specified Employees. In the event that the Executive is a “specified employee” (as described in Section 409A), and any payment or benefit payable pursuant to this Agreement constitutes deferred compensation subject to the six-month delay requirement described in Section 409A(2)(b), then no such payment or benefit shall be made before six months after the Executive’s “separation from service” (as described in Section 409A) (or, if earlier, the date of the Executive’s death). Any payment or benefit delayed by reason of the prior sentence shall be paid out or provided in a single lump sum at the end of such required delay period in order to catch up to the original payment schedule. |
| d) | Treatment of Each Installment as a Separate Payment. For purposes of applying the provisions of Section 409A to this Agreement, each separately identified amount to which the Executive is entitled under this Agreement shall be treated as a separate payment. In addition, to the extent permissible under Section 409A, any series of installment payments under this Agreement shall be treated as a right to a series of separate payments. |
| 7 |
4.6 Severability. It is mutually agreed and understood by the Parties that should any of the restrictions and covenants contained in Article 3 be determined by any court of competent jurisdiction to be invalid by virtue of being vague, overly broad, unreasonable as to time, territory or otherwise, then the Agreement shall be amended retroactive to the date of its execution to include the terms and conditions which such court deems to be reasonable and in conformity with the original intent of the parties and the parties hereto consent that under such circumstances, such court shall have the power and authority to determine what is reasonable and in conformity with the original intent of the parties to the extent that such restrictions and covenants are enforceable. In the event any other provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Agreement, and the Agreement shall be construed and enforced as if the illegal or invalid provision had not been included.
4.7 Modification. No provision of this Agreement may be modified, waived, or discharged unless such modification, waiver, or discharge is agreed to in writing and signed by the Executive and by an authorized officer of the Company on the Company’s behalf, or by the respective parties’ legal representations and successors.
4.8 Dispute Resolution & Applicable Law. All disputes regarding this agreement shall resolved by arbitration to be administered by the American Arbitration Association (Employment Arbitration Rules and Mediation Procedures) or JAMS ADR (Employment Rules and Procedures), except to the extent that the Company or Executive seeks injunctive relief before a court of competent jurisdiction. The Company and the Executive shall pay all costs peculiar to the arbitration (and/or mediation, if applicable), including arbitrator’s fees, and the administration, forum and filing fees equally. This Agreement shall be governed by, and construed in accordance with and subject to, the laws of the State of New York applicable to agreements made and to be performed entirely within such state or torts without regard to its conflicts of law rules.
4.9 Legal Fees and Expenses. The prevailing party of any arbitration to enforce the terms of this Agreement shall be entitled to recover reasonable costs and expenses, including reasonable attorneys’ fees.
4.10 Successors and Assigns. This Agreement shall inure to the benefit of and be enforceable by the Company’s and the Executive’s successors, heirs, and assigns.
4.11 Headings/References. The headings in this Agreement are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.
4.12 Notices. Any notice, request, instruction, or other document to be given hereunder shall be in writing and shall be deemed to have been given: (a) on the day of receipt, if sent by overnight courier (with a courtesy copy also sent by email, which will not alter or extend the date deemed to have been given); (b) upon receipt, if given in person; (c) five days after being deposited in the mail, certified or registered mail, postage prepaid, and in any case addressed as follows:
If to the Company:
105 Maxess Road
Melville, New York 11747
Attn: Chief Financial Officer
with copy sent to the attention of the Chairman of the Board of Directors at the same address.
If to the Executive:
5 Carlton Drive
Norton, MA 02766
or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party.
| 8 |
IN WITNESS WHEREOF, the parties have executed this Agreement on this 13TH day of August 2025.
| SHARPS TECHNOLOGY, INC. |
| By: | /s/ Andrew Crescenzo | |
| Name: | Andrew Crescenzo | |
| Title: | Chief Financial Officer |
EXECUTIVE |
||
| By: | /s/ Paul Danner | |
| Name: | Paul K. Danner | |
| 9 |
EXHIBIT A
EXECUTIVE’S COMPENSATION AND BENEFITS
| 1. | Base Salary: $258,000 per year. |
| 2. | Takeover Bonus: The Company shall pay a one-time Change in Control bonus in the amount of One Hundred Thousand Dollars ($100,000) on the first day of the calendar month immediately following the month in which a Change in Control occurs. For purposes of this provision, a “Change of Control” shall mean the occurrence of any one of the following events: (i) a sale, lease, exclusive license or other disposition of all of substantially all of the assets of the Company; (ii) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the shareholders of the Company immediately prior to such consolidation, merger or reorganization, own less than fifty percent (50%) of the Company’s outstanding voting power of the surviving entity following the consolidation, merger or reorganization; or (iii) any transaction (or series of related transactions involving a person or entity, or a group of affiliated persons or entities) in which in excess of fifty percent (50%) of the Company’s then- outstanding voting power is transferred, excluding any consolidation or merger effected exclusively to change the domicile of the Company and excluding any such change of voting power resulting from a bona fide equity financing event or public offering of the stock of the Company. |
| 3. | Equity Incentive Plan: Executive shall be eligible to participate in the Company’s Equity Incentive Plan disbursements commensurate with his position and responsibilities. |
| 4. | Paid Time Off (PTO): Executive shall be granted up to 25 days of PTO per year, increasing to 30 days of PTO per year after Executive’s second year of service with the Company. Executive may not carry over any unused PTO from prior years. The effective date of initial service for purposes of calculating PTO shall be defined as July 1, 2025. |
| 5. | Health & Welfare Benefits: Executive shall be eligible to participate in all health and welfare benefits as provided by the Company (other than any severance plans). |
| 6. | Retirement Benefits: Executive shall be eligible to participate in all retirement benefits as provided by the Company. |
ACKNOWLEDGED AND AGREED:
| SHARPS TECHNOLOGY, INC. |
| By: | /s/ Andrew Crescenzo | |
| Name: | Andrew Crescenzo | |
| Title: | Chief Financial Officer |
EXECUTIVE |
||
| By: | /s/ Paul Danner | |
| Paul K. Danner | ||
| 10 |
EXHIBIT B
FORM OF RELEASE
GENERAL RELEASE OF CLAIMS
1. Paul K. Danner (“Executive”), for himself and his family, heirs, executors, administrators, legal representatives and their respective successors and assigns, in exchange for the Severance Benefits, as defined under the Executive Employment Agreement made and entered effective as of the 1st day of July 2025, by and between Sharps Technology, Inc., a Nevada Corporation (the “Company”) and Paul K. Danner (the “Executive”), to which this release is attached as Exhibit B (the “Employment Agreement”), does hereby release and forever discharge the Company, its subsidiaries, affiliated companies, successors and assigns, and its current or former directors, officers or shareholders in such capacities (collectively with the Company, the “Released Parties”) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or in connection with Executive’s employment or termination thereof, whether for tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment. Executive acknowledges that the Company encouraged him to consult with an attorney of his choosing, and through this General Release of Claims encourages him to consult with his attorney with respect to possible claims under the Age Discrimination in Employment Act (“ADEA”) and that he understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided above, Executive expressly waives any and all claims under ADEA that he may have as of the date hereof. Executive further understands that by signing this General Release of Claims he is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i) any rights to receive any payments or benefits to which Executive is entitled under COBRA, the Employment agreement or any other compensation or employee benefit plans in which Executive is eligible to participate at the time of execution of this General Release of Claims, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, any indemnification and advancement rights Executive may have as a former employee, officer or director of the Company or its subsidiaries or affiliated companies including, without limitation, any rights arising pursuant to the articles of incorporation, bylaws and any other organizational documents of the Company or any of its subsidiaries, (iii) any claims for benefits under any directors’ and officers’ liability policy maintained by the Company or its subsidiaries or affiliated companies in accordance with the terms of such policy, and (iv) any rights as a holder of equity securities of the Company (clauses (i) through (iv), the “Reserved Claims”).
2. Executive represents that he has not filed against the Released Parties any complaints, charges, or lawsuits arising out of his employment, or any other matter arising on or prior to the date of this General Release of Claims other than Reserved Claims, and covenants and agrees that he will never individually or with any person file, or commence the filing of any lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Executive pursuant to paragraph 1 hereof (a “Proceeding”); provided, however, Executive shall not have relinquished his right to (i) commence a Proceeding to challenge whether Executive knowingly and voluntarily waived his rights under ADEA; (ii) file a charge with an administrative agency or take part in any agency investigation or (iii) commence a Proceeding pursuant to the Reserved Claims. Executive does agree, however, that he is waiving his right to recover any money in connection with such an investigation or charge filed by him or by any other individual, or a charge filed by the Equal Employment Opportunity Commission or any other federal, state or local agency, except as prohibited by law.
3. Executive hereby acknowledges that the Company has informed him that he has up to twenty-one (21) days to sign this General Release of Claims and he may knowingly and voluntarily waive that twenty-one (21) day period by signing this General Release of Claims earlier. Executive also understands that he shall have seven (7) days following the date on which he signs this General Release of Claims within which to revoke it by providing a written notice of his revocation to the Company.
4. Executive acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the laws of New York, without giving effect to any choice of law principles.
5. Executive acknowledges that he has read this General Release of Claims, that he has been advised that he should consult with an attorney before he executes this general release of claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof.
6. This General Release of Claims shall take effect on the eighth day following Executive’s execution of this General Release of Claims unless Executive’s written revocation is delivered to the Company within seven (7) days after such execution.
EXECUTIVE |
||
| /s/ Paul Danner | ||
| By: | Paul K. Danner | |
| 11 |
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
I, Robert M. Hayes, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of Sharps Technology, Inc. (the Registrant); |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared; | |
| b) | Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| c) | Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
| 5. | The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent function): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and | |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| /s/ Robert M. Hayes | |
| Robert M. Hayes | |
| Chief Executive Officer (Principal Executive Officer) | |
| Date: August 13, 2025 |
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
I, Andrew R. Crescenzo, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of Sharps Technology, Inc. (the Registrant); |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and we have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b) | Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| c) | Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
| 5. | The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent function): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and | |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
| /s/ Andrew R. Crescenzo | |
| Andrew R. Crescenzo | |
| Chief Financial Officer (Principal Financial Officer) | |
| Date: August 13, 2025 |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the accompanying Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2025, I, Robert M. Hayes, Chief Executive Officer of Sharps Technology, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
| (1) | Such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2025, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) | The information contained in such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2025, fairly presents, in all material respects, the financial condition and results of operations of Sharps Technology, Inc. |
| /s/ Robert M. Hayes | |
| Robert M. Hayes | |
| Chief Executive Officer (Principal Executive Officer) | |
| Date: August 13, 2025 |
A signed original of the certification required by Section 906 has been provided to Sharps Technology, Inc. and will be retained by Sharps Technology, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the accompanying Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2025 I, Andrew R. Crescenzo, Chief Financial Officer of Sharps Technology, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
| (1) | Such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2025, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) | The information contained in such Quarterly Report on Form 10-Q of Sharps Technology, Inc. for the period ended June 30, 2025, fairly presents, in all material respects, the financial condition and results of operations of Sharps Technology, Inc. |
| /s/ Andrew R. Crescenzo | |
| Andrew R. Crescenzo | |
| Chief Financial Officer (Principal Financial Officer) | |
| Date: August 13, 2025 |
A signed original of the certification required by Section 906 has been provided to Sharps Technology, Inc. and will be retained by Sharps Technology, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.